Recent studies have centered on the intersection of GLP|GIP|GCGR stimulant therapies and dopaminergic signaling. While GIP agonists are widely employed for managing type 2 diabetes, their emerging effects on reinforcement circuits, specifically influenced by dopamine pathways, are receiving signi